Literature DB >> 19539050

Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.

Richard Boyce1, Carol Collins, John Horn, Ira Kalet.   

Abstract

We describe a novel experiment that we conducted with the Drug Interaction Knowledge-base (DIKB) to determine which combinations of evidence enable a rule-based theory of metabolic drug-drug interactions to make the most optimal set of predictions. The focus of the experiment was a group of 16 drugs including six members of the HMG-CoA-reductase inhibitor family (statins). The experiment helped identify evidence-use strategies that enabled the DIKB to predict significantly more interactions present in a validation set than the most rigorous strategy developed by drug experts with no loss of accuracy. The best-performing strategies included evidence types that would normally be of lesser predictive value but that are often more accessible than more rigorous types. Our experimental methods represent a new approach to leveraging the available scientific evidence within a domain where important evidence is often missing or of questionable value for supporting important assertions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539050      PMCID: PMC2783683          DOI: 10.1016/j.jbi.2009.05.010

Source DB:  PubMed          Journal:  J Biomed Inform        ISSN: 1532-0464            Impact factor:   6.317


  52 in total

1.  Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.

Authors:  T Zimmermann; R A Yeates; H Laufen; F Scharpf; M Leitold; A Wildfeuer
Journal:  Arzneimittelforschung       Date:  1996-02

2.  Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.

Authors:  D S Greene; D E Salazar; R C Dockens; P Kroboth; R H Barbhaiya
Journal:  J Clin Psychopharmacol       Date:  1995-12       Impact factor: 3.153

3.  Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

Authors:  D J Black; K L Kunze; L C Wienkers; B E Gidal; T L Seaton; N D McDonnell; J S Evans; J E Bauwens; W F Trager
Journal:  Drug Metab Dispos       Date:  1996-04       Impact factor: 3.922

4.  A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.

Authors:  N Yasui; K Otani; S Kaneko; T Ohkubo; T Osanai; K Sugawara; K Chiba; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1996-05       Impact factor: 6.875

5.  The effect of ingestion time interval on the interaction between itraconazole and triazolam.

Authors:  P J Neuvonen; A Varhe; K T Olkkola
Journal:  Clin Pharmacol Ther       Date:  1996-09       Impact factor: 6.875

6.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.

Authors:  A Varhe; K T Olkkola; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

7.  Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.

Authors:  R H Barbhaiya; U A Shukla; P D Kroboth; D S Greene
Journal:  J Clin Psychopharmacol       Date:  1995-10       Impact factor: 3.153

8.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.

Authors:  L L von Moltke; D J Greenblatt; J S Harmatz; S X Duan; L M Harrel; M M Cotreau-Bibbo; G A Pritchard; C E Wright; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

9.  Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.

Authors:  A Varhe; K T Olkkola; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1996-04       Impact factor: 4.335

10.  Diltiazem enhances the effects of triazolam by inhibiting its metabolism.

Authors:  A Varhe; K T Olkkola; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

View more
  14 in total

1.  High-priority drug-drug interactions for use in electronic health records.

Authors:  Shobha Phansalkar; Amrita A Desai; Douglas Bell; Eileen Yoshida; John Doole; Melissa Czochanski; Blackford Middleton; David W Bates
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

2.  Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.

Authors:  Casey Lynnette Overby; Emily Beth Devine; Peter Tarczy-Hornoch; Ira J Kalet
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

Review 3.  Informatics confronts drug-drug interactions.

Authors:  Bethany Percha; Russ B Altman
Journal:  Trends Pharmacol Sci       Date:  2013-02-13       Impact factor: 14.819

4.  Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.

Authors:  Richard T Scheife; Lisa E Hines; Richard D Boyce; Sophie P Chung; Jeremiah D Momper; Christine D Sommer; Darrell R Abernethy; John R Horn; Stephen J Sklar; Samantha K Wong; Gretchen Jones; Mary L Brown; Amy J Grizzle; Susan Comes; Tricia Lee Wilkins; Clarissa Borst; Michael A Wittie; Daniel C Malone
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

5.  Towards a foundational representation of potential drug-drug interaction knowledge.

Authors:  Mathias Brochhausen; Jodi Schneider; Daniel Malone; Philip E Empey; William R Hogan; Richard D Boyce
Journal:  CEUR Workshop Proc       Date:  2014-10

6.  Toward a complete dataset of drug-drug interaction information from publicly available sources.

Authors:  Serkan Ayvaz; John Horn; Oktie Hassanzadeh; Qian Zhu; Johann Stan; Nicholas P Tatonetti; Santiago Vilar; Mathias Brochhausen; Matthias Samwald; Majid Rastegar-Mojarad; Michel Dumontier; Richard D Boyce
Journal:  J Biomed Inform       Date:  2015-04-24       Impact factor: 6.317

Review 7.  Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics.

Authors:  Heng-Yi Wu; Aditi Shendre; Shijun Zhang; Pengyue Zhang; Lei Wang; Desta Zeruesenay; Luis M Rocha; Hagit Shatkay; Sara K Quinney; Xia Ning; Lang Li
Journal:  Clin Pharmacol Ther       Date:  2020-02-03       Impact factor: 6.875

8.  Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness.

Authors:  Richard D Boyce; John R Horn; Oktie Hassanzadeh; Anita de Waard; Jodi Schneider; Joanne S Luciano; Majid Rastegar-Mojarad; Maria Liakata
Journal:  J Biomed Semantics       Date:  2013-01-26

9.  The SADI Personal Health Lens: A Web Browser-Based System for Identifying Personally Relevant Drug Interactions.

Authors:  Ben Vandervalk; E Luke McCarthy; José Cruz-Toledo; Artjom Klein; Christopher J O Baker; Michel Dumontier; Mark D Wilkinson
Journal:  JMIR Res Protoc       Date:  2013-04-05

10.  Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.

Authors:  Jon D Duke; Xu Han; Zhiping Wang; Abhinita Subhadarshini; Shreyas D Karnik; Xiaochun Li; Stephen D Hall; Yan Jin; J Thomas Callaghan; Marcus J Overhage; David A Flockhart; R Matthew Strother; Sara K Quinney; Lang Li
Journal:  PLoS Comput Biol       Date:  2012-08-09       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.